Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus
|| Print ||
|Tuesday, 20 July 2010 10:00 (UTC + 2)|
Rottapharm Madaus, the multinational pharmaceutical company, has signed a drug discovery research contract with Selvita - Poland based product and solution provider for the pharmaceutical and biotechnology industry.
Krakow, Poland, July 20, 2010 / b3c newswire / - Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.
"We are very pleased and honoured that we can cooperate with such a prestigious multinational pharmaceutical company as Rottapharm Madaus" – said Pawel Przewiezlikowski, Selvita’s CEO. "This project is an immense chance for Selvita to show the great potential of our Computational Chemistry and Chemistry Departments. Working for Rottapharm Madaus on this project will enable us to take a full advantage of our highly skilled scientists and new facilities, and I truly believe we can deliver exactly what Rottapharm Madaus needs. I’m looking forward to this cooperation very much.”
About Rottapharm - www.rotta.com
Rottapharm is a multinational pharmaceutical company with Italian capital, established in Monza, Italy in 1961. Since its beginning, Rottapharm was characterized by a strong commitment to research: in almost 50 years, Rottapharm ‘s scientists synthesized thousands lead compounds on specific molecular targets, generating more than 300 patents and 19 original drugs. Rottapharm R&D is focused on therapeutic areas such as: rheumatology, gynaecology, urology, gastroenterology, bronchopneumology, psychiatry, oncology. In 2000, through the acquisition of major brands in intimate hygiene and paediatric care, such as the Saugella and Babygella brands, Rottapharm has entered the personal care market in the pharmacy, further strengthening its position thereafter. In 2007, Rottapharm performed the largest M & A transaction ever made by an Italian pharmaceutical company, through the acquisition of the German group Madaus Pharma.
About SELVITA - www.selvita.com